Adrenal Sampling in Hyperaldosteronism With Contrast Allergy Adrenal Sampling in Hyperaldosteronism With Contrast Allergy
A patient with primary hyperaldosteronism and a severe allergy to contrast media was able to successfully undergo adrenal vein sampling using dexamethasone as premedication.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 19, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Letter to the Editor: Dexamethasone Works for Acute Back Pain
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - October 1, 2021 Category: Emergency Medicine Tags: Letter to the Editor Source Type: news

Adding Remdesivir to Dexamethasone Early Associated With Better Outcomes of Moderate COVID-19 Adding Remdesivir to Dexamethasone Early Associated With Better Outcomes of Moderate COVID-19
Adding remdesivir to dexamethasone is associated with better clinical outcomes of COVID-19, especially when done early in the treatment of mild to moderate disease, according to new research.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 10, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Dr. Bryan Ardis talks warns that covid hospital protocols are needlessly killing patients – Brighteon.TV
(Natural News) The Thrive Time Show sat down with Dr. Bryan Ardis to talk about how COVID-19 protocols that hospitals are required to follow are actually killing patients. According to Ardis, hospitals dictate the protocols for COVID-19 treatment, and among these protocols include the use of drugs remdesivir, dexamethasone, and vancomycin — drugs, that, together, can... (Source: NaturalNews.com)
Source: NaturalNews.com - September 8, 2021 Category: Consumer Health News Source Type: news

Dexamethasone Studied for Treatment of Heavy Menstrual Bleeding
WEDNESDAY, Aug. 18, 2021 -- Low-dose dexamethasone may reduce heavy menstrual bleeding (HMB) when taken during the luteal phase of menstrual cycles, according to a study published online recently in EBioMedicine. Pamela Warner, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 18, 2021 Category: Pharmaceuticals Source Type: news

Study Finds Underuse of Dexamethasone in COVID Patients Study Finds Underuse of Dexamethasone in COVID Patients
Dexamethasone, now an evidence-based treatment for severe COVID-19, is under-utilized in the United States, a new analysis shows.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 17, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Dexamethasone Can Help the Sickest COVID Patients Survive. So Why Are Too Few Getting It?
TUESDAY, Aug. 17, 2021 -- There's strong evidence that the steroid drug dexamethasone can significantly lower hospitalized patients'risk of dying from COVID-19, but many who might benefit from it the most aren't getting it. " Dexamethasone is a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 17, 2021 Category: General Medicine Source Type: news

Dexamethasone Underused for Adults Hospitalized With COVID - 19
Dexamethasone and remdesivir use have gradually increased during the pandemic; hydroxychloroquine use peaked in March 2020 (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 17, 2021 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news

Dexamethasone Underused for Adults Hospitalized With COVID-19
MONDAY, Aug. 16, 2021 -- For adults hospitalized with COVID-19, dexamethasone and remdesivir use increased over time, although dexamethasone is still somewhat underused, according to a study published online Aug. 17 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2021 Category: Pharmaceuticals Source Type: news

Are corticosteroids given orally or by injection an effective treatment for people with COVID-19?
 Are corticosteroids (anti-inflammatory medicines) given orally or by injection an effective treatment for people with COVID-19?Key messagesCorticosteroids (anti-inflammatory medicines) given orally or by injection (systemic) are probably effective treatments for people hospitalised with COVID-19.   The authors don’t know whether they cause unwanted effects. The authorsdon ’t know which systemic corticosteroid is the most effective. They found no evidence about people without symptoms or with mild COVID-19 who were not hospitalised. They found 42 ongoing studies and 16 completed studies that...
Source: Cochrane News and Events - August 10, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news

Namibia: Unicef Donates 400,000 Dexamethasone Injections to Help With the Covid-19 Fight
[Namibia Economist] Namibia Health Ministry recently received 400,000 vials of Dexamethasone injections from UNICEF, to support the treatment of COVID-19 patients. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 4, 2021 Category: African Health Source Type: news

Coronavirus live: UK reports 138 deaths amid 21,691 new cases; row in Germany over jabbing children
UK deaths are highest since mid-March;doctors, scientists and the government disagree over vaccinating children in GermanyUS Covid hospitalisations rise as doctors say patients are unvaccinatedNew York to require vaccination for indoor dining and eventsScotland to scrap social distancing as it lifts most restrictionsHundreds of health workers in isolation as Delta hits QueenslandHopes UK vaccine trial in pregnant women will allay jab fears5.58pmBSTOvernight, the board of governors of the International Monetary Fund (IMF) approved the largest resource injection in its history to boost global liquidity and help countries whi...
Source: Guardian Unlimited Science - August 3, 2021 Category: Science Authors: Mattha Busby (now); Miranda Bryant, Robyn Vinter and Helen Livingstone (earlier) Tags: Coronavirus World news Science Infectious diseases New Zealand Japan US news Source Type: news

Covid drug could help reduce heavy menstrual bleeding
Trial suggests anti-inflammatory dexamethasone may offer welcome alternative to intra-uterine systemResearchers hope a steroid that shot to prominence during the Covid pandemic may help reduce blood loss in those who experience heavy periods.The cheap anti-inflammatory dexamethasone was discoveredto improve survival rates among patients critically ill with Covid. It isalso used for conditions including severe asthma and certain forms of arthritis.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 3, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Medical research Menstruation Science Pharmaceuticals industry UK news Women Health Source Type: news

£5 Covid drug dexamethasone could combat heavy periods for millions of women, study claims
Research by the University of Edinburgh shows dexamethasone - which only £5 per patient - can be used to treat women who have prolonged bleeding during menstruation. (Source: the Mail online | Health)
Source: the Mail online | Health - August 3, 2021 Category: Consumer Health News Source Type: news

Duration of Maintenance Therapy Studied in Childhood ALL
Vincristine and dexamethasone pulses might be eliminated during second year of treatment for children with low - risk disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 2, 2021 Category: Cancer & Oncology Tags: Oncology, Pediatrics, Pharmacy, Journal, Source Type: news

Duration of Maintenance Therapy Studied in Childhood ALL
MONDAY, Aug. 2, 2021 -- For patients with low-risk childhood acute lymphoblastic leukemia, the omission of seven pulses of therapy with vincristine and oral dexamethasone during the second year of maintenance therapy might not worsen treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 2, 2021 Category: Pharmaceuticals Source Type: news

Miracle drug is 'life saving' against Covid and will stop hospital treatment, GPs claim 
MPs last night called on NHS England to look into more at-home use of the steroid Dexamethasone to further cut cases of serious illness from Covid. The drug has mostly been used in hospitals. (Source: the Mail online | Health)
Source: the Mail online | Health - August 1, 2021 Category: Consumer Health News Source Type: news

Community-acquired bacterial meningitis
Progress has been made in the prevention and treatment of community-acquired bacterial meningitis during the past three decades but the burden of the disease remains high globally. Conjugate vaccines against the three most common causative pathogens (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae) have reduced the incidence of disease, but with the replacement by non-vaccine pneumococcal serotypes and the emergence of bacterial strains with reduced susceptibility to antimicrobial treatment, meningitis continues to pose a major health challenge worldwide. In patients presenting with bacterial m...
Source: Current Awareness Service for Health (CASH) - July 28, 2021 Category: Consumer Health News Source Type: news

Ivermectin for preventing and treating COVID-19
This study reported results for development of COVID-19 symptoms (but not confirmed SARS-CoV-2 infection) and unwanted events, but in a way that we could not include in our analyses. This study did not look at hospital admissions.Main results explainedMain authors of the review, Maria Popp and Stephanie Weibel said: “The lack of good quality evidence on efficacy and safety of ivermectin arises from a study pool that consists mainly of small, insufficiently powered RCTs with overall limited quality regarding study design, conduct, and reporting. Current evidence does not support using ivermectin for treating o r preve...
Source: Cochrane News and Events - July 22, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

When is Post-Operative Bleeding Most Likely to Occur after a Tonsillectomy?
Discussion Tonsillectomy is one of the most commonly performed surgical procedures in the US with pressure equalizing tubes and circumcisions also being among the top procedures. About 500,000 are performed yearly in the US in children under 15 years. Primary indications are recurrent throat infections (e.g. “
Source: PediatricEducation.org - July 19, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone HORSHAM, Pa., July 12, 2021 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Co... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, DARZALEX FASPRO®, daratumumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2021 Category: Pharmaceuticals Source Type: news

FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 12, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Hemady (dexamethasone)
Title: Hemady (dexamethasone)Category: MedicationsCreated: 6/29/2021 12:00:00 AMLast Editorial Review: 6/29/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 29, 2021 Category: Cancer & Oncology Source Type: news

Uganda: Pharmacists Warn Against Dexamethasone Use As Covid Drug
[Monitor] Pharmacists have asked doctors to stop prescribing dexamethasone for Covid-19 patients undergoing home-based care, saying the medicine lowers immunity and increases the risk of developing severe disease. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - June 24, 2021 Category: African Health Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

What Are Some Indications for Using Dexamethasone?
Discussion Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

New study may help explain low oxygen levels in COVID-19 patients
A new study published in the journal Stem Cell Reports by University of Alberta researchers is shedding light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia--a potentially dangerous condition in which there is decreased oxygenation in the body's tissues. The study also shows why the anti-inflammatory drug dexamethasone has been an effective treatment for those with the virus. (Source: World Pharma News)
Source: World Pharma News - June 2, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New study may help explain low oxygen levels in COVID-19 patients
(University of Alberta Faculty of Medicine& Dentistry) A new study by University of Alberta researchers sheds light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia--a potentially dangerous condition in which there is decreased oxygenation in the body's tissues. The study also shows why the anti-inflammatory drug dexamethasone has been an effective treatment. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 2, 2021 Category: Infectious Diseases Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Lies Beneath: The Sorcerer's Apprentice and Dexamethasone
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - June 1, 2021 Category: Emergency Medicine Tags: What Lies Beneath Source Type: news

Selinexor, bortezomib, dexamethasone cost effective in previously treated multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Cortisol Secretion, Mortality Link Explored in Adrenal Incidentalomas
WEDNESDAY, May 26, 2021 -- For patients with adrenal incidentalomas, autonomous cortisol secretion is associated with mortality at a plasma cortisol level after a 1-mg dexamethasone suppression test (cortisolDST) of 83 nmol/L or higher, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2021 Category: Pharmaceuticals Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mild Cortisol Excess Increases Mortality in Adrenal Incidentaloma Mild Cortisol Excess Increases Mortality in Adrenal Incidentaloma
Autonomous cortisol secretion level following dexamethasone suppression test in patients with adrenal incidentalomas but without Cushing syndrome found to have prognostic value.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - May 24, 2021 Category: Infectious Diseases Tags: Diabetes & Endocrinology News Source Type: news

DDMA asks pharmacies to display available stock, cost of COVID-19 drugs prominently
The drugs are Ivermectin tablets, Doxycyclin tablets/capsule, Methyl Prednisolone tablets and injections, Dexamethasone tablets and injections, Budosenide Inhalers and Respules Favipiravir tablets, Apixaban tablets and Enoxaparin Sodium/ Clexane, it said. (Source: The Economic Times)
Source: The Economic Times - May 22, 2021 Category: Consumer Health News Source Type: news

Maxidex (dexamethasone) Suspension
Title: Maxidex (dexamethasone) SuspensionCategory: MedicationsCreated: 5/21/2021 12:00:00 AMLast Editorial Review: 5/21/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 21, 2021 Category: Drugs & Pharmacology Source Type: news

Maxitrol (neomycin and polymyxin B sulfates and dexamethasone)
Title: Maxitrol (neomycin and polymyxin B sulfates and dexamethasone)Category: MedicationsCreated: 5/21/2021 12:00:00 AMLast Editorial Review: 5/21/2021 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - May 21, 2021 Category: Opthalmology Source Type: news

Preoperative DEX and Cognitive Function After Cardiac Surgery Preoperative DEX and Cognitive Function After Cardiac Surgery
Might prophylactic administration of dexamethasone reduce the risk of postoperative cognitive decline?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2021 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Dexamethasone Does Not Increase Risk for Surgical-Site Infection
FRIDAY, May 7, 2021 -- For adults undergoing nonurgent, noncardiac surgery, dexamethasone is noninferior to placebo with respect to surgical-site infection within 30 days, according to a study published in the May 6 issue of the New England Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2021 Category: Pharmaceuticals Source Type: news

Dexamethasone for Nausea Does Not Raise Risk of Surgical-Site Infections Dexamethasone for Nausea Does Not Raise Risk of Surgical-Site Infections
Fears that dexamethasone may increase the risk of surgical-site infection when given to prevent nausea and vomiting after an operation appear to be unfounded.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 6, 2021 Category: Surgery Tags: General Surgery News Source Type: news

FDA D.I.S.C.O. Burst: Approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four lines of prior therapy
Listen to a soundcast of the February 26, 2021 FDA approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adults patients with refractory multiple myeloma who received at least four prior lines of therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Steroids Can Be Stopped in Some Older Myeloma Patients Steroids Can Be Stopped in Some Older Myeloma Patients
In intermediate-fit elderly patients newly diagnosed with multiple myeloma, dexamethasone can be stopped during maintenance without having an adverse effect on outcome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 31, 2021 Category: Drugs & Pharmacology Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
Progression - free, three - year overall survival similar for lenalidomide maintenance regimen without dexamethasone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 24, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
WEDNESDAY, March 24, 2021 -- Dose/schedule-adjusted lenalidomide-dexamethasone (Rd) followed by a maintenance regimen of lenalidomide 10 mg/day without dexamethasone (Rd-R) is feasible for older patients with multiple myeloma (MM), with survival... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2021 Category: Pharmaceuticals Source Type: news

New figures show dexamethasone treatment for COVID-19 has so far saved 22,000 lives in UK, NHS England (published 23rd March 2021)
These figures were released by NHS England, who noted dexamethasone has also saved ~1 million lives worldwide since the positive findings from RECOVERY trial of decreased risk of death by a third in patients on ventilators and by almost a fifth in those on oxygen. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 24, 2021 Category: Consumer Health News Source Type: news

COVID treatment developed in the NHS saves a million lives
Dexamethasone, an inexpensive and widely available steroid, has saved around one million lives worldwide since its discovery as an effective treatment for COVID-19 in a clinical trial in the NHS. (Source: NHS Networks)
Source: NHS Networks - March 23, 2021 Category: UK Health Source Type: news

Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both month...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news